VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Cancer recombinant vector vaccine encoding H-2Kb Prostate cancer DNA vaccine hPSMAt encoding PSMA Prostate cancer DNA vaccine rPSMAt encoding PSMA
Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0011368
  • Type: Recombinant vector vaccine
  • Status: Research
  • H2-K1 gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Vector: Recombinant adenovirus (Campbell et al., 2000).
  • Immunization Route: i.t. injection
  • Vaccine Ontology ID: VO_0004446
  • Type: DNA vaccine
  • Status: Research
  • Prostate-specific membrane antigen gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pVAX1 expressed human prostate-specific membrane antigen, PSMA (Mincheff et al., 2006).
    • Detailed Gene Information: Click Here.
  • Vector: pVAX1
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004447
  • Type: DNA vaccine
  • Status: Research
  • Prostate-specific membrane antigen gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pVAX1 expressed rat prostate-specific membrane antigen, PSMA (Mincheff et al., 2006).
    • Detailed Gene Information: Click Here.
  • Vector: pVAX1 (Mincheff et al., 2006)
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response Host Response

Rat Response

  • Host Strain: Fisher 344
  • Vaccination Protocol: A study was conducted to examine the growth inhibition of LN-4 tumors in vivo with an intratumoral (i.t.) injection of AdV-H-2Kb adenovirus. Fisher 344 rats were injected s.c. in their right thighs with 0.5x106 LN-4 tumor cells. At 2 weeks after tumor inoculation, when tumors grew to ;3–4 mm in diameter, rats were injected i.t. with a single dose of 2.5x109 PFU of the AdV-H2Kb virus. The i.t. injection of the AdV-H-2Kb virus was given two more times at 5-day intervals for a total of three injections. As a control, rats were injected i.t. with a single dose of 2.5x109 PFU of the AdV5LacZ adenovirus (Campbell et al., 2000).
  • Efficacy: The expression of xenogeneic MHC class I antigen completely abolished the LN-4 tumorigenicity in rats, whereas the expression of allogeneic MHC class I antigen only partially reduced the MCA-26 tumorigenicity in mice. The immunized rats that experienced LN-4/H-2Kb tumor regression further developed protective immunity against a subsequent challenge of LN-4 cells. Adenovirus-mediated H-2Kb gene transfer in vivo can further significantly inhibit pre-established LN-4 tumors (Campbell et al., 2000).

Rat Response

  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: Only two of the 10 animals immunized against human PSMA developed tumors. In contrast, 17 of the 20 animals in the control groups developed tumors. The tumors, developing in the group, immunized with the human construct, were smaller than the ones in the control group (Mincheff et al., 2006).

Rat Response

  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: Only five of the 10 animals immunized against the rat analogue developed tumors. In contrast, 17 of the 20 animals in the control groups developed tumors. The tumors developing in the group immunized with the rat construct were smaller than the ones in the control group (Mincheff et al., 2006).
References References References
Campbell et al., 2000: Campbell I, Moyana T, Carlsen S, Zheng C, Xiang J. Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth. Cancer gene therapy. 2000; 7(1); 37-44. [PubMed: 10678354].
Mincheff et al., 2006: Mincheff M, Zoubak S, Makogonenko Y. Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals. Cancer gene therapy. 2006; 13(4); 436-444. [PubMed: 16276349].
Mincheff et al., 2006: Mincheff M, Zoubak S, Makogonenko Y. Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals. Cancer gene therapy. 2006; 13(4); 436-444. [PubMed: 16276349].